What is HC Wainwright’s Estimate for ODTX FY2026 Earnings?

Odyssey Therapeutics, Inc. (NASDAQ:ODTX – Free Report) – Equities research analysts at HC Wainwright issued their FY2026 earnings estimates for Odyssey Therapeutics in a report issued on Friday, November 6th. HC Wainwright analyst J. Pantginis expects that the company will post earnings per share of ($6.20) for the year. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Odyssey Therapeutics’ current full-year earnings is ($6.18) per share. HC Wainwright also issued estimates for Odyssey Therapeutics’ Q4 2026 earnings at ($1.26) EPS, FY2027 earnings at ($5.14) EPS, FY2028 earnings at ($5.03) EPS, FY2029 earnings at ($5.22) EPS and FY2030 earnings at ($4.83) EPS.

Other equities research analysts have also issued reports about the company. Raymond James Financial assumed coverage on Odyssey Therapeutics in a research report on Thursday, October 8th. They set an “outperform” rating and a $42.00 price target on the stock. Weiss Ratings assumed coverage on Odyssey Therapeutics in a research report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. JPMorgan Chase & Co. boosted their price objective on Odyssey Therapeutics from $26.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. Finally, UBS Group assumed coverage on Odyssey Therapeutics in a research note on Monday, October 12th. They issued a “buy” rating and a $27.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.67.

Check Out Our Latest Analysis on ODTX

Odyssey Therapeutics Price Performance

NASDAQ:ODTX opened at $20.99 on Tuesday. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $29.05. The firm has a 50 day moving average price of $20.91.

Institutional Trading of Odyssey Therapeutics

Several hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new stake in shares of Odyssey Therapeutics in the third quarter valued at approximately $28,000. The Manufacturers Life Insurance Company acquired a new position in Odyssey Therapeutics during the 2nd quarter worth $601,000. State Street Corp acquired a new position in Odyssey Therapeutics during the 2nd quarter worth $1,477,000. Aberdeen Group plc lifted its holdings in Odyssey Therapeutics by 4.7% during the 3rd quarter. Aberdeen Group plc now owns 172,771 shares of the company’s stock worth $3,839,000 after buying an additional 7,771 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Odyssey Therapeutics during the 2nd quarter worth $4,162,000.

Key Stories Impacting Odyssey Therapeutics

Investors following ODTX have been watching these stories:

  • Positive Sentiment: Odyssey announced a publication describing the differentiated therapeutic potential of TNFR2 agonism, offering investors encouraging scientific support for its research program. Article: Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism
  • Positive Sentiment: HC Wainwright maintained a Buy rating and a $40 price target. Its forecasts anticipate ongoing losses, but improving from an estimated $6.20 per share in 2026 to $4.83 per share in 2030; the target is well above the stock’s recent trading level. MarketBeat ODTX coverage
  • Negative Sentiment: HC Wainwright’s estimates still project Odyssey will remain unprofitable through 2030, a reminder of the ongoing funding and development risks facing the biotech company.

Odyssey Therapeutics Company Profile

(Get Free Report)

Odyssey Therapeutics is a biotechnology company focused on discovering and developing medicines for inflammatory and autoimmune diseases. Its research centers on the immune system and biological pathways that may be targeted to address these conditions. Founded in 2021, the company uses drug-discovery capabilities to identify and advance potential therapies. Its business is research and development rather than the sale of marketed medicines. Odyssey is based in the United States. As a research-focused biotechnology company, its activities are centered on developing potential treatments rather than serving patients through a broad commercial product operation.

Featured Articles

Earnings History and Estimates for Odyssey Therapeutics (NASDAQ:ODTX)

Receive News & Ratings for Odyssey Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odyssey Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.